Neurocrine presents one-year data from study of Crenessity

Neurocrine (NBIX) Biosciences announced the presentation of new one-year data from the CAHtalyst Adult study of Crenessity showing that patients achieved lasting, more physiologic glucocorticoid doses, while adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione remained at or below baseline levels. These data complement the recently announced CAHtalyst Pediatric one-year results and were presented at the Endocrine Society’s Annual Meeting, ENDO 2025, that is taking place July 12-15 in San Francisco. “Results from the pivotal CAHtalyst clinical trial program continue to reinforce the critical role of Crenessity in the management of classic congenital adrenal hyperplasia,” said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. “These one-year data show the lasting ability of Crenessity to effectively manage the ACTH and adrenal steroid imbalances in adults while allowing for lower, more physiologic steroid dosing and improved clinical outcomes.”